LifeVantage

LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The firm operates through the following geographical segments: Americas Region, and Asia/Pacific and Europe Region. Its products include Protandim, LifeVantage Omega+ and ProBio, TrueScience and Petandim for dogs. The company was founded in June 1988 and is headquartered in Sandy, UT.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

LifeVantage reports 7.5% revenue growth, eyes expansion into new markets

LifeVantage's Q1 2023 results reflect strong revenue growth driven by the Americas region and successful product launches. The company's LV360 initiative and new compensation plan have shown promising results. However, challenges in the Asia Pacific and Europe region need to be addressed. The fiscal 2023 outlook presents opportunities for continued growth and expansion into new markets.

LifeVantage reports revenue growth in Q2, driven by LV360 strategy

LifeVantage's Q2 saw revenue growth, improved engagement, and successful resolution of supply chain challenges. The introduction of LV360 and product innovations drove performance. Challenges in supply chain management persist, but opportunities for growth are present.

LifeVantage reports revenue growth and product innovation in Q3

LifeVantage's Q3 performance reflects revenue growth, strong financials, and product innovation, with a focus on market expansion.
While challenges exist in regional revenue declines and market uncertainties, the company's strengths in the Americas region and product launches offer growth opportunities.
Maintaining financial stability, enhancing consultant growth, and leveraging new products position LifeVantage for continued success and market leadership.
Overall, LifeVantage's strategic initiatives and financial performance indicate a resilient business model with growth potential and shareholder value.

LifeVantage reports strong Q4 earnings, unveils special dividend for shareholders

LifeVantage's Q4 2023 results reflect robust revenue growth and improved profitability, driven by strategic initiatives and product performance. The company's commitment to shareholder value through dividends and its transformation plan underscores a positive outlook for future growth. While challenges exist, opportunities in product innovation and market expansion position LifeVantage well for continued success.

LifeVantage posts robust Q1 results, eyes international growth opportunities

LifeVantage delivered a strong Q1 2024 performance with revenue growth and improved profitability, driven by successful product sales and international expansion.
Despite challenges like currency fluctuations, the company's financial stability, strategic capital allocation, and growth outlook position it well for future success.
Opportunities in product innovation, international markets, and strategic investments underscore potential avenues for continued growth and value creation for shareholders.
Investors can be optimistic about LifeVantage's trajectory, supported by its solid financial foundation and clear strategic focus on maximizing shareholder value.

LifeVantage reports strong Q2 earnings, eyes growth through product innovation

LifeVantage showcased robust financial performance with notable EBITDA growth and revenue per consultant increase, despite a slight revenue decline.
The company's focus on product innovation, market expansion, and shareholder value enhancement positions it well for future growth and competitiveness.
Strategies to address revenue challenges, capitalize on growth opportunities, and navigate market dynamics will be crucial for sustained success.

LifeVantage reports robust Q3 performance amidst revenue challenges and growth opportunities

LifeVantage demonstrated strong operational performance and profitability improvements in Q3, despite revenue challenges.
The company's focus on consultant enrollment, new product launches, and financial stability are key strengths.
While facing revenue and margin pressures, LifeVantage has opportunities to drive growth through market expansion and product optimization.
Strategic initiatives to address challenges and capitalize on opportunities will be crucial for sustained success in future quarters.

LifeVantage reports Q4 results, eyes growth with loyalty programs

LifeVantage's Q4 2024 performance showed revenue decline but improved margins and strategic initiatives.
Strengths lie in loyalty program enhancements, positive financials, and a promising outlook for fiscal 2025.
Challenges include leadership changes, revenue decline, and the need for sustained growth in active accounts.
Opportunities exist in product launches, retention strategies, and market expansion for the company's growth.
headline

LifeVantage reports robust Q1 earnings, eyes international expansion for growth

LifeVantage's Q1 2025 showcased strong profitability despite revenue decline, driven by the successful MindBody GLP-1 System launch.
Guidance for fiscal 2025 indicates a positive outlook with revenue and EBITDA projections, supported by plans for international product expansion.
While facing revenue challenges, the company's focus on innovation, market demand, and strategic growth initiatives present opportunities for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LifeVantage Corp. engages in the identification, research, development, formulation, and sale of nutraceutical dietary supplements and personal care products. Its products include Protandim, Axio, TrueScience, PhysIQ, and Petandim. It operates through the Americas, and Asia or Pacific and Europe geographical segments. The company was founded in June 1988 and is headquartered in Lehi, UT.

Steven R. Fife Named President, CEO & Director Steven R. Fife Named President, CEO & Director

LifeVantage Announces Appointment of Chief Executive Officer

LifeVantage Corporation (LFVN) Interim CEO Steve Fife on Q1 2021 Results - Earnings Call Transcript

LifeVantage Corporation (LFVN) Interim CEO Steve Fife on Q1 2021 Results - Quick Version Earnings Call Transcript

First Quarter Adjusted EPS and Adjusted EBITDA Increased 92% and 43%, respectively

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2021

SALT LAKE CITY, Oct. 20, 2020 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that it will release financial results for its first quarter ended September 30, 2020, after the stock market closes on Tuesday, November 3, 2020. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.

LifeVantage to Announce First Quarter Fiscal Year 2021 Results on November 3, 2020

Steven Fife Appointed Interim Chief Executive Officer

LifeVantage Announces Management Transition

SALT LAKE CITY, Aug.  27, 2020  (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that Darren Jensen, the Company's President and Chief Executive Officer and Steve Fife, Chief Financial Officer, will participate in two upcoming investor conferences virtually.  These include the LD Micro 500, to be held September 1-4, 2020 and the H.C. Wainwright 22nd Annual Global Investment Conference to be held September 14-16.

LifeVantage to Participate in Upcoming Investor Conferences

LifeVantage Corporation (LFVN) CEO Darren Jensen on Q4 2020 Results - Earnings Call Transcript

Record Fiscal 2020 Revenue of $233 million

LifeVantage Announces Financial Results for the  Fourth Fiscal Quarter and Full Fiscal Year 2020

SALT LAKE CITY, Aug.  04, 2020  (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that it will release financial results for its fourth quarter and full fiscal year ended June 30, 2020, after the stock market closes on Tuesday, August 18, 2020. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.

LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2020 Results on August 18, 2020

LifeVantage's (LFVN) CEO Darren Jensen on Q3 2020 Results - Earnings Call Transcript

Philip Morris

Westlake Chemical Partners LP

In order to unearth stocks of strong businesses that are reasonably priced and are capable of generating high returns, I looked for companies with the following characteristics:

3 Stocks With Attractive Valuations

LifeVantage Corp (LFVN) CEO Darren Jensen on Q2 2020 Results - Earnings Call Transcript

Preliminary revenue of approximately $61 million represents the highest quarterly revenue in company history

LifeVantage Posts Record Second Quarter Preliminary Revenue, Introduces Free Shipping in 2020

SALT LAKE CITY, Nov.  12, 2019  (GLOBE NEWSWIRE) -- As part of its continued global expansion, LifeVantage Corporation (Nasdaq:LFVN) has formally commenced business in New Zealand.

LifeVantage Opens for Business in New Zealand

LifeVantage Corporation (LFVN) CEO Darren Jensen on Q1 2020 Results - Earnings Call Transcript

LifeVantage Corporation (LFVN) CEO Darren Jensen on Q4 2019 Results - Earnings Call Transcript

LifeVantage has recently shown upward trend after some years of negative events.

Consider LifeVantage Corp. As A Taste Of The Dietary Supplements Market

LifeVantage Corporation (LFVN) CEO Darren Jensen on Q3 2019 Results - Earnings Call Transcript

News for LifeVantage Stock (LFVN)